Adenosine A2A and A2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts.
We aimed to test if stimulation of both adenosine A2A and A2B receptors is required to produce an effective cardioprotection against reperfusion injury. Isolated rat hearts were subjected to 30-min regional ischemia followed by 2 h of reperfusion. The adenosine A1/A2 receptor agonist 5'-(N-ethylcarboxamido) adenosine (NECA) given at reperfusion reduced infarct size, an effect that was reversed by both the adenosine A2A antagonist SCH58261 and the A2B antagonist MRS1706. The A2B agonist BAY 60-6583 but not the selective A2A agonist CGS21680 reduced infarct size. Interestingly, a combination of BAY 60-6583 and CGS21680 further reduced infarct size. These results suggest that both A2A and A2B receptors are involved in NECA's anti-infarct effect at reperfusion. NECA attenuated mitochondrial swelling upon reperfusion and this was blocked by both SCH58261 and MRS1706, indicating that activation of A2 receptors with NECA can modulate reperfusion-induced mitochondrial permeability transition pore (mPTP) opening. In support, NECA also prevented oxidant-induced loss of mitochondrial membrane potential (DeltaPsi(m)) and matrix Ca2+ overload in cardiomyocytes via both the A2 receptors. In addition, NECA increased mitochondrial glycogen synthase kinase-3beta (GSK-3beta) phosphorylation upon reperfusion and this was again blocked by SCH58261 and MRS1706. In conclusion, A2A and A2B receptors work in concert to prevent reperfusion injury in rat hearts treated with NECA. NECA may protect the heart by modulating the mPTP opening through inactivating mitochondrial GSK-3beta. A simultaneous stimulation of A2A and A2B receptors at reperfusion is required to produce a strong cardioprotection against reperfusion injury.
Xi
Jinkun
J
Department of Anesthesiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
McIntosh
Rachel
R
Shen
Xiangjun
X
Lee
SungRyul
S
Chanoit
Guillaume
G
Criswell
Hugh
H
Zvara
David A
DA
Xu
Zhelong
Z
D019830:Adenosine-5'-(N-ethylcarboxamide) / Q000494:pharmacology; D000818:Animals; D015153:Blotting, Western; D006321:Heart / Q000187:drug effects; D008297:Male; D018613:Microscopy, Confocal; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D043705:Receptor, Adenosine A2A / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D043704:Receptor, Adenosine A2B / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D015427:Reperfusion Injury / Q000139:chemically induced / Q000517:prevention & control*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014665:Vasodilator Agents / Q000494:pharmacology
D043705:Receptor, Adenosine A2A; D043704:Receptor, Adenosine A2B; D014665:Vasodilator Agents; D019830:Adenosine-5'-(N-ethylcarboxamide)
J Mol Cell Cardiol. 2007 Nov;43(5):564-70
17931653
Cardiovasc Res. 2004 Feb 15;61(3):372-85
14962470
Anesthesiology. 2008 Feb;108(2):243-50
18212569
Cardiovasc Drugs Ther. 2003 Sep-Nov;17(5-6):415-25
15107596
J Mol Cell Cardiol. 2004 Mar;36(3):411-21
15010280
J Mol Cell Cardiol. 2007 Sep;43(3):262-71
17632123
Am J Physiol. 1996 May;270(5 Pt 2):H1655-61
8928871
Am J Physiol Heart Circ Physiol. 2005 Mar;288(3):H1290-5
15528225
Cardiovasc Res. 2003 Dec 1;60(3):617-25
14659807
Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H1825-33
18757481
Cardiovasc Res. 2007 Jul 15;75(2):426-33
17570352
Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2523-9
17675570
J Pharmacol Exp Ther. 1997 Jan;280(1):301-9
8996210
Cardiovasc Res. 2005 Mar 1;65(4):803-12
15721860
Biophys J. 2000 Jul;79(1):39-50
10866936
Am J Physiol. 1996 Oct;271(4 Pt 2):H1456-64
8897940
Eur J Pharmacol. 2009 Feb 14;604(1-3):111-6
19135050
Circulation. 2008 May 27;117(21):2761-8
18490522
Cardiovasc Res. 2005 Jul 1;67(1):124-33
15949476
Biochem J. 1995 Apr 1;307 ( Pt 1):93-8
7717999
J Cardiovasc Pharmacol. 1993 Jul;22(1):89-96
7690102
Basic Res Cardiol. 2006 Jul;101(4):319-26
16604438
Cardiovasc Res. 2006 May 1;70(2):308-14
16545350
Am Heart J. 1992 Feb;123(2):332-8
1736567
Circ Res. 1995 Feb;76(2):242-51
7834835
Circ Res. 2002 Mar 8;90(4):390-7
11884367
Circulation. 2005 Jan 18;111(2):194-7
15642769
Am J Physiol Heart Circ Physiol. 2008 Dec;295(6):H2328-35
18849340
J Cardiovasc Pharmacol. 2001 Sep;38(3):474-81
11486252
Circ Res. 2003 Aug 22;93(4):292-301
12933700
Circulation. 2007 Mar 27;115(12):1581-90
17353435
J Pharmacol Exp Ther. 2006 Jul;318(1):124-31
16611852
Am J Physiol Heart Circ Physiol. 2008 Sep;295(3):H1288-H1295
18660452
Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):382-91
11111832
J Mol Cell Cardiol. 2001 Jan;33(1):57-68
11133223
Cardiovasc Res. 1997 May;34(2):337-47
9205548
J Mol Cell Cardiol. 2006 May;40(5):708-16
16516918
Pharmacol Rev. 1997 Dec;49(4):381-402
9443164
J Clin Invest. 2004 Jun;113(11):1535-49
15173880
Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H2079-86
18805899